A natural virus library
Nearly 30 non-pathogenic natural viruses, bioselected for their ability to preferentially infect and kill cancer cells. Drawn from the human enterovirus class, which carries decades of cumulative safety data.
A Cleveland biotech · For cancers without answers
Nature's own viruses
fighting
hard-to-treat cancers.
Nonpathogenic, naturally occurring human enterovirus strains that possess a high potency for killing cancer cells — in vitro and in vivo — backed by decades of clinical and population-level safety data for the parent enterovirus class.
~30
OVs in library
9
Cancer programs
3
US patents issued
1
Notice of allowance
Naturally
occurring
occurring
Library origin
Problem & solution
Limitations of current Oncolytic Viruses (OVs) and how Sator solves them
Oncolytic virotherapy has shown that viruses can selectively kill cancer cells while sparing healthy tissue, and trigger durable immune responses — a promising new modality for patients who exhaust conventional options. But the current generation of engineered OVs runs into seven recurring limitations that have held back broader clinical benefit. Sator's platform is designed to address each.
Current OV limitations
Sator approach
Pre-existing immunity
Most clinical OVs use common human pathogens (HSV, adenovirus, vaccinia, measles).
No pre-existing immunity
Non-pathogenic enterovirus strains absent from common circulation — no prior human immunity.
Narrow therapeutic window
Strong neutralizing antibody response within weeks; virus cannot treat relapses.
Extended therapeutic window
Sequential multi-virus strategy bypasses neutralizing antibodies.
Single-virus monotherapy
Tumors are heterogeneous — resistant subclones can evade a single virus and drive relapse.
Multi-virus combinatorial
Combinatorial approach tackles tumor cell diversity and immune resistance.
Systemic toxicity
Pathogenic or armed viruses risk systemic cytokine storms; most are limited to direct tumor injection.
Designed for IV delivery
Non-pathogenic enterovirus strains are intended to circulate intravenously and reach metastatic disease, leveraging the safety footprint of related naturally-occurring viruses.
Local-only immunity
Intratumoral injection primes an immunostimulatory response at the injected tumor only — local, not body-wide.
Body-wide priming
IV delivery reaches every tumor site, priming a body-wide immunostimulatory response — leading to systemic anti-tumor immunity.
No biomarkers
Poor patient selection depresses response rates and complicates trial design.
Companion diagnostics
Patient gating selects permissive tumors — enriches for responders, de-risks trials.
Genomic instability
Engineered transgenes can drift or revert during GMP scale-up; potency and batch consistency suffer.
Genomic stability
Natural genomes replicate stably through GMP production; consistent batch-to-batch potency.
Naturally-occurring enteroviruses carry decades of accumulated human safety data: from global vaccination programs delivered to hundreds of millions of recipients, and from routine human exposure to viruses in natural circulation. This deep human exposure history provides a strong scientific baseline for Sator's safety hypothesis, to be confirmed through IND-enabling studies and subsequent clinical trials. Sator's product candidates have not yet been evaluated in formal clinical trials.
Our approach
Methods. Delivery. Pipeline. All protected.
Sator combines a library of natural viruses — its STR series — with combinatorial dosing methods, IV administration, and a dendritic-cell carrier. For each cancer indication, candidate STR viruses are screened in vitro on two parameters, efficacy and safety, and only the intersection of both progresses into development. Three issued US patents and one recent Notice of Allowance protect the methods, delivery, and pipeline.
Patent portfolio
Together they cover combinatorial dosing methods, the dendritic-cell delivery system, codon-optimized next-generation candidates, and a parallel veterinary application.
US Patent 11,253,558 · Issued Feb 22, 2022
Combinatorial natural-virus dosing
Optimized Oncolytic Viruses and Uses Thereof
Covers Sator’s combinatorial-use approach to oncolytic virotherapy with naturally-occurring, primarily picornavirus-family viruses (echoviruses and coxsackieviruses), including both sequential dosing within a defined time window and simultaneous administration of multiple viruses with different host-cell receptors, designed to overcome neutralizing antibody responses.
US Patent 12,357,664 · Issued Jul 15, 2025
Codon-optimized & evolved synthetic viruses
Optimized Oncolytic Viruses and Uses Thereof
Two methods: (i) generating synthetic oncolytic viruses by re-coding reference virus sequences with codons optimized for the target cancer cell’s translation machinery, and (ii) generating optimized variants — including antibody-resistant ones — through directed evolution with mutagenic ribonucleoside analogs. Expands Sator’s IP estate from the naturally-occurring library into engineered and evolved candidates, with demonstrated faster killing of rapidly proliferating cancer cells.
US App. Ser. No. 17/543,333 · Notice of Allowance Sept 12, 2025
Veterinary oncology applications
Optimized Oncolytic Viruses and Uses Thereof
Methods of treating tumors in dogs and cats, explicitly including mastocytoma, osteosarcoma, and mammary carcinoma, using proprietary protocols including multi-virus cocktails, opening a parallel veterinary oncology application targeting the largest companion-animal cancer markets.
US Patent 12,606,796 · Issued Apr 21, 2026
Dendritic cell delivery system
Delivery of Oncolytic Viruses Using Dendritic Cells
Composition-of-matter coverage of dendritic cells loaded with oncolytic viruses (such as vaccinia), autologous or allogeneic, plus methods for high-efficiency DC loading via neutralizing-antibody complexation and pharmacokinetically-guided adaptive sequential dosing. Completes Sator’s patent coverage of its core delivery strategy.
Four applications, working together.
Whole-body IV delivery
Systemic IV administration is designed to reach metastatic tumor sites throughout the body and target cancer stem cell populations in hard-to-treat tumors.
Sequential & combination dosing
Widens the therapeutic window: different viruses delivered over successive doses outpace neutralizing antibody responses and hit tumors through multiple independent mechanisms.
Dendritic cell carriers
Our patented delivery platform hides the virus inside dendritic cells, shielding it from circulating immunity and escorting it directly to the tumor.
Companion diagnostics
Personalized medicine, without the guesswork
Sator's proprietary algorithm is designed to predict how a patient will respond to a specific virus before treatment — without the cost and weeks-long delay of culturing their tumor cells in the lab. Knowing in advance avoids treating patients who won't benefit, and addresses the field's central problem: current cancer-killing viruses help only 10–20% of patients.
Match patient to virus
Sator's pipeline includes multiple viral candidates — the algorithm selects the virus or combination most likely to drive a response for a given patient.
Know before you treat
The algorithm predicts each patient's response before treatment begins, turning a clinical guess into an evidence-based decision.
Lift the response ceiling
Historically, single-agent oncolytic virotherapy has hit a 10–20% response rate ceiling. Our patient-virus matching model is designed to raise the patient success rate by ensuring each treatment is precisely targeted to a likely responder.
Diagnostic decisions in days
Existing pathology feeds directly into the algorithm — bypassing the multi-week cell culture step in many cases — shortening the gap between diagnosis and the start of treatment.
Cancer programs
Nine programs. One platform
One lead indication selected for mechanism alignment and regulatory pathway. Eight additional programs span hard-to-treat solid cancers where current treatments fall short.
Lead indication
Mesothelioma
Pleural · Asbestos-linked · ~12-month median overall survival on current standard-of-care.
Pleural mesothelioma is an aggressive cancer arising from the mesothelial lining of the pleura, almost always linked to historical asbestos exposure. Roughly 3,000 new US cases annually places it well below the FDA Orphan Drug Designation eligibility threshold of 200,000 patients. The disease profile aligns directly with Sator's mechanism: IV-administered oncolytic virotherapy is designed to reach pleural tumor sites and disseminated disease that intratumoral approaches cannot consistently access.
US incidence
~3,000 new cases / year
Regulatory path
Eligible to apply for FDA Orphan Drug Designation
Development stage
Preclinical in vivo activity
The broader pipeline
Active programs
Breast
Triple-negative and hormone-receptor-negative subtypes — ~30,000 US TNBC cases annually with poor metastatic prognosis.
Ovarian
Platinum-resistant disease recurring within 6 months of chemotherapy. Few effective second-line options.
Glioblastoma
Aggressive primary brain tumor, ~15-month median survival on standard chemoradiation. Systemic vs. intratumoral delivery.
Bladder
Muscle-invasive disease with substantial recurrence after cystectomy and adjuvant chemotherapy.
Research programs
Pancreatic
Most lethal solid tumor by 5-year survival. Immune-cold microenvironment; KRAS-mutant across most patients.
Melanoma
Checkpoint-refractory disease — anti-PD-1 fails 40–60% of metastatic patients.
Osteosarcoma
Pediatric and young-adult bone cancer with limited progress in recurrent disease for decades. Few effective options after first-line chemotherapy.
Comparative oncology
Companion-animal programs (canine, feline) — translational data plus parallel veterinary commercial pathway.
Market context
Oncolytic virotherapy is reaching maturity
The oncolytic virus field is poised for a breakthrough decade, with billions in strategic deal activity and a clear regulatory path for differentiated platforms. Sator's combination of naturally-occurring viruses, systemic delivery, and sequential dosing is purpose-built for the indications where current OV candidates fall short.
$4B+
OV deal activity
Disclosed deal value across oncolytic virus partnerships and acquisitions has exceeded four billion dollars, signaling deep strategic commitment from large biopharma.
Orphan eligible
Regulatory pathway
Straightforward CMC and clinical development paths. Sator's lead programs are expected to be eligible to apply for US FDA Orphan Drug Designation and biologic exclusivity. If and when granted, these would provide market exclusivity and patent-life extension on top of a growing IP estate.
Natural · Systemic
Our differentiation
Approved and late-stage OVs are engineered and injected into tumors directly. Sator's library is naturally-occurring, administered systemically, and delivered in sequential combinations: a different therapeutic profile for a different patient population.
Newsroom
Recent milestones
A record of Sator's corporate, patent, and platform milestones. Detailed technical and business updates are available through the investor portal.
U.S. Patent issued for dendritic cell delivery platform
The U.S. Patent and Trademark Office issued U.S. Patent No. 12,606,796 B2 — “Delivery of Oncolytic Viruses Using Dendritic Cells” — to Sator Therapeutics on April 21, 2026. The granted claims cover composition-of-matter rights to dendritic cells loaded with oncolytic viruses, plus methods for high-efficiency DC loading and pharmacokinetically-guided sequential dosing. This is Sator’s third issued U.S. patent and completes formal protection of its core delivery strategy.
USPTO Notice of Allowance for dendritic cell delivery platform application
U.S. Patent Application Serial No. 16/868,691 — “Delivery of Oncolytic Viruses Using Dendritic Cells” — received a Notice of Allowance from the U.S. Patent and Trademark Office on February 5, 2026. The allowed claims cover Sator's dendritic-cell-mediated systemic delivery platform, completing the company's patent coverage of its core delivery strategy. (The patent subsequently issued as U.S. 12,606,796 B2 on April 21, 2026.)
Leadership discusses codon optimization and dendritic cell delivery in published industry interview
Sator's Chief Technology Officer outlined the company's patented approach to synonymous codon optimization and its dendritic cell delivery carrier in a two-part published interview with manufacturing partner Batavia Biosciences, describing how the platform aims to overcome neutralizing antibody responses that have limited conventional oncolytic virus response rates.
Notice of Allowance for veterinary oncology methods application
U.S. Patent Application Serial No. 17/543,333 — a continuation in the “Optimized Oncolytic Viruses and Uses Thereof” family — received a Notice of Allowance on September 12, 2025. The allowed claims cover methods of treating animal cancers with Sator's oncolytic viruses, opening a parallel veterinary oncology application of the platform.
US Patent 12,357,664 issued for codon-optimized synthetic oncolytic viruses
U.S. Patent No. 12,357,664 — “Optimized Oncolytic Viruses and Uses Thereof” — was issued by the USPTO on July 15, 2025. The patent describes methods of creating next-generation codon-optimized synthetic viruses targeting cancerous tumors, expanding the company's IP estate beyond the naturally-occurring library.
Sator leadership presents oncolytic virotherapy platform to Rotary Club of Cleveland
Company leadership presented Sator's natural-virus oncology platform to the Rotary Club of Cleveland, outlining the company's patent-protected approach and its broader mission of advancing oncolytic virus therapies for patients with hard-to-treat cancers.
US Patent 11,253,558 issued for combinatorial use of oncolytic viruses
U.S. Patent No. 11,253,558 — “Optimized Oncolytic Viruses and Uses Thereof” — was issued by the USPTO on February 22, 2022. The patent covers Sator's signature combinatorial-use approach to oncolytic virotherapy, including both sequential and simultaneous administration of multiple viruses to overcome neutralizing antibody responses.
Note on forward-looking content. This newsroom summarizes publicly verifiable events in Sator's corporate and intellectual-property history. Patent application publication does not constitute a grant of patent rights, and Notices of Allowance precede the formal issuance of patent claims. Please see the disclaimers at the bottom of this page.
Engage with Sator
Two ways to work with us
Whether you're a patient advocate, a scientific collaborator, or an investor tracking the oncolytic virus space, there's a path into Sator that fits. Pick the one that matches your interest.
Send a message
Get in touch
Strategic partnerships, scientific collaborations, patient or caregiver questions, press inquiries, students. We read every message and route it to the right person at Sator. We do our best to respond, even if we can’t always share everything publicly.
Pharma, partners, patients & press Request investor accessEquity investment
Capital is being raised to fund IND-enabling studies for the lead mesothelioma program, with formal clinical trials planned as the next step. A complete data room — clinical precedent, patent portfolio, preclinical activity data, and commercial strategy — is available to qualified investors under NDA. Access requires a brief qualification step.
For investorsFor cancers without answers.
Sator Therapeutics develops naturally-occurring, non-pathogenic oncolytic viruses designed to selectively kill cancer cells in hard-to-treat tumors. Whole-body delivery. Sequential dosing. No genetic engineering.
Naturally selective.
Systemically deliverable.
Sator is advancing toward formal clinical development. Join the scientific, clinical, and investor partners helping us get there.
Already have investor portal credentials? Sign in →